Awakn Life Sciences Corp.
AWKNF · OTC
1/31/2024 | 1/31/2023 | 1/31/2022 | 1/31/2021 | |
|---|---|---|---|---|
| Market Cap | $4 | $9 | $44 | $24 |
| - Cash | $0 | $1 | $2 | $0 |
| + Debt | $0 | $2 | $2 | $0 |
| Enterprise Value | $3 | $10 | $44 | $24 |
| Revenue | $0 | $1 | $0 | $0 |
| % Growth | -94.2% | 533.5% | – | – |
| Gross Profit | $0 | $1 | -$0 | $0 |
| % Margin | 100% | 59.6% | -117.3% | – |
| EBITDA | -$4 | -$5 | -$16 | -$1 |
| % Margin | -4,473% | -352% | -6,814.6% | – |
| Net Income | -$5 | -$9 | -$16 | -$1 |
| % Margin | -5,840.1% | -611.4% | -6,755.7% | – |
| EPS Diluted | -0.18 | -0.36 | -0.73 | -0.1 |
| % Growth | 50% | 50.7% | -631.5% | – |
| Operating Cash Flow | -$2 | -$7 | -$9 | -$0 |
| Capital Expenditures | $0 | -$0 | -$2 | -$0 |
| Free Cash Flow | -$2 | -$7 | -$10 | -$1 |